Pillai N, Liu N, Li X, Li X, Ahrens-Nicklas R, Adang L
Commun Med (Lond). 2025; 5(1):12.
PMID: 39789203
PMC: 11718225.
DOI: 10.1038/s43856-024-00703-8.
Zhou L, Wang Y, Xu Y, Zhang Y, Zhu C
Mol Ther Methods Clin Dev. 2024; 32(4):101357.
PMID: 39559557
PMC: 11570947.
DOI: 10.1016/j.omtm.2024.101357.
Dickson P
Mol Ther. 2024; 32(11):3756-3757.
PMID: 39481371
PMC: 11573562.
DOI: 10.1016/j.ymthe.2024.10.008.
Presa M, Pham V, Ray S, Piec P, Ryan J, Billings T
Commun Med (Lond). 2024; 4(1):215.
PMID: 39448727
PMC: 11502872.
DOI: 10.1038/s43856-024-00648-y.
Yalcin K, Uygun V, Ozturk Hismi B, Celen S, Ozturkmen S, Zhumatayev S
Bone Marrow Transplant. 2024; 60(1):47-51.
PMID: 39402187
DOI: 10.1038/s41409-024-02439-4.
Ready-to-use iPSC-derived microglia progenitors for the treatment of CNS disease in mouse models of neuropathic mucopolysaccharidoses.
Douvaras P, Buenaventura D, Sun B, Lepack A, Baker E, Simpson E
Nat Commun. 2024; 15(1):8132.
PMID: 39284802
PMC: 11405712.
DOI: 10.1038/s41467-024-52400-8.
Gene therapy for the leukodystrophies: From preclinical animal studies to clinical trials.
Metovic J, Li Y, Gong Y, Eichler F
Neurotherapeutics. 2024; 21(4):e00443.
PMID: 39276676
PMC: 11418141.
DOI: 10.1016/j.neurot.2024.e00443.
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond.
Zanetti A, Tomanin R
BioDrugs. 2024; 38(5):639-655.
PMID: 39177874
PMC: 11358193.
DOI: 10.1007/s40259-024-00675-0.
The top 100 most cited articles on mucopolysaccharidoses: a bibliometric analysis.
Liao R, Geng R, Yang Y, Xue Y, Chen L, Chen L
Front Genet. 2024; 15:1377743.
PMID: 38680422
PMC: 11045982.
DOI: 10.3389/fgene.2024.1377743.
Hematopoietic Stem Cell Transplantation for Storage Disorders: Present Status.
Chakraborty S, Gupta A, Gupta N, Meena J, Seth R, Kabra M
Indian J Pediatr. 2024; 91(8):830-838.
PMID: 38639861
DOI: 10.1007/s12098-024-05110-4.
Molecular Mechanisms in Pathophysiology of Mucopolysaccharidosis and Prospects for Innovative Therapy.
Ago Y, Rintz E, Musini K, Ma Z, Tomatsu S
Int J Mol Sci. 2024; 25(2).
PMID: 38256186
PMC: 10816168.
DOI: 10.3390/ijms25021113.
Hurler Syndrome Glycosaminoglycans Decrease in Cerebrospinal Fluid without Brain-Targeted Therapy.
Lund T, Braunlin E, Polgreen L, Gupta A, Orchard P, Eisengart J
Ann Neurol. 2023; 94(6):1182-1186.
PMID: 37679306
PMC: 11318530.
DOI: 10.1002/ana.26786.
Neurologic Recovery in MPS I and MPS II Mice by AAV9-Mediated Gene Transfer to the CNS After the Development of Cognitive Dysfunction.
Podetz-Pedersen K, Laoharawee K, Singh S, Nguyen T, Smith M, Temme A
Hum Gene Ther. 2022; 34(1-2):8-18.
PMID: 36541357
PMC: 10024071.
DOI: 10.1089/hum.2022.162.
AAVrh10 vector corrects pathology in animal models of GM1 gangliosidosis and achieves widespread distribution in the CNS of nonhuman primates.
Hocquemiller M, Giersch L, Mei X, Gross A, Randle A, Gray-Edwards H
Mol Ther Methods Clin Dev. 2022; 27:281-292.
PMID: 36320411
PMC: 9594110.
DOI: 10.1016/j.omtm.2022.10.004.
MPSI Manifestations and Treatment Outcome: Skeletal Focus.
De Ponti G, Donsante S, Frigeni M, Pievani A, Corsi A, Bernardo M
Int J Mol Sci. 2022; 23(19).
PMID: 36232472
PMC: 9569890.
DOI: 10.3390/ijms231911168.
Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases.
Heller G, Bradbury A, Sands M, Bongarzone E
Mol Ther. 2022; 31(1):7-23.
PMID: 36196048
PMC: 9840155.
DOI: 10.1016/j.ymthe.2022.09.017.
GCAF(TMEM251) regulates lysosome biogenesis by activating the mannose-6-phosphate pathway.
Zhang W, Yang X, Li Y, Yu L, Zhang B, Zhang J
Nat Commun. 2022; 13(1):5351.
PMID: 36096887
PMC: 9468337.
DOI: 10.1038/s41467-022-33025-1.
Hematopoietic Stem Cell Transplantation for Neurological Disorders: A Focus on Inborn Errors of Metabolism.
de Vasconcelos P, Lacerda J
Front Cell Neurosci. 2022; 16:895511.
PMID: 35693884
PMC: 9178264.
DOI: 10.3389/fncel.2022.895511.
Isogenic GAA-KO Murine Muscle Cell Lines Mimicking Severe Pompe Mutations as Preclinical Models for the Screening of Potential Gene Therapy Strategies.
Aguilar-Gonzalez A, Gonzalez-Correa J, Barriocanal-Casado E, Ramos-Hernandez I, Lerma-Juarez M, Greco S
Int J Mol Sci. 2022; 23(11).
PMID: 35682977
PMC: 9181599.
DOI: 10.3390/ijms23116298.
Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?.
Horgan C, Jones S, Bigger B, Wynn R
Int J Mol Sci. 2022; 23(9).
PMID: 35563245
PMC: 9105950.
DOI: 10.3390/ijms23094854.